Spots Global Cancer Trial Database for refractory aml
Every month we try and update this database with for refractory aml cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML | NCT01191801 | Acute Myeloid L... | vosaroxin + cyt... placebo + cytar... | 18 Years - | Sunesis Pharmaceuticals | |
| Natural Killer Cell (CYNK-001) Infusions in Adults With AML | NCT04310592 | Leukemia Leukemia, Myelo... Leukemia, Myelo... Neoplasms by Hi... Neoplasms Immunosuppressi... Immunologic Fac... Physiological E... Alkylating Agen... Antimetabolites... Antiviral Agent... Analgesics, Non... Anti-infective ... Analgesics Peripheral Nerv... Hematologic Dis... Hematologic Neo... Leukemia in Rem... Relapsed Adult ... Refractory AML | CYNK-001 | 18 Years - 80 Years | Celularity Incorporated | |
| An Early Phase Study of NEI-01 in Patients With Solid Tumors or Acute Myeloid Leukemia | NCT05226468 | Advanced Solid ... Relapsed AML Refractory AML | NEI-01 | 18 Years - | New Epsilon Innovation Limited | |
| Granulocyte Colony Stimulating Factor (G-CSF) After Salvage Chemotherapy in Refractory AML | NCT02427919 | Leukemia, Myelo... | G-CSF | 17 Years - 64 Years | Seoul St. Mary's Hospital | |
| A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I) | NCT00317642 | Acute Myelogeno... | clofarabine (IV... placebo cytarabine | 55 Years - | Sanofi | |
| Sertraline and Cytosine Arabinoside in Adults With Relapsed and Refractory AML | NCT02891278 | Acute Myeloid L... | Sertraline Cytosine arabin... allogeneic stem... | 18 Years - 70 Years | Columbia University | |
| Bisantrene for Relapsed /Refractory AML | NCT03820908 | Acute Myelogeno... Allogeneic Stem... | Bisantrene | 18 Years - | Sheba Medical Center | |
| Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia | NCT06022003 | AML, Adult Refractory AML Relapsed Adult ... FLT3-TKD Mutati... FLT3-ITD | AzaCITIDine Ora... Xospata | 18 Years - | French Innovative Leukemia Organisation | |
| Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia | NCT06022003 | AML, Adult Refractory AML Relapsed Adult ... FLT3-TKD Mutati... FLT3-ITD | AzaCITIDine Ora... Xospata | 18 Years - | French Innovative Leukemia Organisation | |
| Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia | NCT02665065 | Acute Myeloid L... Leukemia, Acute... Myeloid Leukemi... Leukemia, Myelo... Acute Myelogeno... Leukemia, Acute... Myelogenous Leu... AML Bone Marrow Tra... | Iomab-B Conventional Ca... HCT | 55 Years - | Actinium Pharmaceuticals | |
| Phase II Study of TPA Plus Dexamethasone & CMT in Hematologic Malignancies | NCT01009931 | Leukemia | 12-O-tetradecan... Dexamethasone Choline magnesi... | 18 Years - | Rutgers, The State University of New Jersey | |
| A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I) | NCT00317642 | Acute Myelogeno... | clofarabine (IV... placebo cytarabine | 55 Years - | Sanofi | |
| Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia | NCT06007911 | Relapsed Adult ... Refractory AML | Navitoclax Dose... Navitoclax Dose... Navitoclax Dose... Navitoclax Dose... Venetoclax Dose... Venetoclax Dose... Cladribine Cytarabine (Cla... Cytarabine (CLA... Mitoxantrone Granulocyte Col... | 18 Years - | Medical College of Wisconsin | |
| Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML | NCT01191801 | Acute Myeloid L... | vosaroxin + cyt... placebo + cytar... | 18 Years - | Sunesis Pharmaceuticals | |
| Combination of Decitabine and Midostaurin in Patients Older Than 60 With Newly Diagnosed or Relapsed Refractory Acute Myeloid Leukemia | NCT01130662 | Acute Myeloid L... | combination the... | 18 Years - | University of Kansas Medical Center | |
| Minnelide in Adult Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT03347994 | Acute Myeloid L... | Minnelide | 18 Years - | University of Miami | |
| Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML | NCT01191801 | Acute Myeloid L... | vosaroxin + cyt... placebo + cytar... | 18 Years - | Sunesis Pharmaceuticals | |
| Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia | NCT03616470 | Acute Myeloid L... | Uproleselan Placebo | 18 Years - 75 Years | GlycoMimetics Incorporated | |
| IMPACT-AML: Randomized Pragmatic Clinical Trial for Relapsed or Refractory AML | NCT06418776 | Refractory Acut... Early Relapses ... | Intensive thera... Low intensity t... | 18 Years - | National Research Center for Hematology, Russia | |
| Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia | NCT03516760 | Acute Myeloid L... Relapsed AML Refractory AML | GEM333 | 18 Years - | AvenCell Europe GmbH | |
| Phase 1 Study of Quizartinib | NCT02675478 | Relapsed AML Refractory AML | AC220 | 20 Years - | Daiichi Sankyo | |
| Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation | NCT02074839 | Relapsed or Ref... Untreated AML Other IDH1-muta... Myelodysplastic... | AG-120 | 18 Years - | Servier | |
| Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia | NCT03616470 | Acute Myeloid L... | Uproleselan Placebo | 18 Years - 75 Years | GlycoMimetics Incorporated | |
| Granulocyte Colony Stimulating Factor (G-CSF) After Salvage Chemotherapy in Refractory AML | NCT02427919 | Leukemia, Myelo... | G-CSF | 17 Years - 64 Years | Seoul St. Mary's Hospital | |
| PR104 in Treating Patients With Refractory/Relapsed Acute Leukemia | NCT01037556 | Acute Myelogeno... Acute Lymphocyt... | PR104 | 18 Years - | Proacta, Incorporated | |
| Natural Killer Cell (CYNK-001) Infusions in Adults With AML | NCT04310592 | Leukemia Leukemia, Myelo... Leukemia, Myelo... Neoplasms by Hi... Neoplasms Immunosuppressi... Immunologic Fac... Physiological E... Alkylating Agen... Antimetabolites... Antiviral Agent... Analgesics, Non... Anti-infective ... Analgesics Peripheral Nerv... Hematologic Dis... Hematologic Neo... Leukemia in Rem... Relapsed Adult ... Refractory AML | CYNK-001 | 18 Years - 80 Years | Celularity Incorporated | |
| Minnelide in Adult Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT03347994 | Acute Myeloid L... | Minnelide | 18 Years - | University of Miami | |
| Alvocidib Biomarker-driven Phase 2 AML Study | NCT02520011 | Acute Myeloid L... | Alvocidib Cytarabine Mitoxantrone | 18 Years - 65 Years | Sumitomo Pharma America, Inc. | |
| Combination of Decitabine and Midostaurin in Patients Older Than 60 With Newly Diagnosed or Relapsed Refractory Acute Myeloid Leukemia | NCT01130662 | Acute Myeloid L... | combination the... | 18 Years - | University of Kansas Medical Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
